he linker payload, mc-MMAD (6-maleimidocaproyl-monomethylauristatin-D) was conjugated to the A1 anti-5T4 monoclonal antibody through a cysteine residue at a ratio of approximately 4 compound moieties per antibody molecule.
|Source||Ther Adv Respir Dis (2018). Figure 3. MMAD|
|Method||Influence of inhalation duration on lung deposition|
|Concentrations||1.5, 3.0, 4.5 μM|
|Results||Other studies also suggest that particles with an MMAD in the range 1.5–4.5 μm can achieve good lung deposition, consistent with these findings.|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10 mM in DMSO|
|Related Microtubule Products|
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity.
DM4, a chemical derivative of maytansine, is a potent and selective cytotoxic agent that inhibit cell division.
VcMMAE is a anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
Crolibulin (also known as EPC2407 and crinobulin) is a small molecule tubulin polymerization inhibitor with potential antineoplastic activity.
Maytansinol, also known as Ansamitocin P-0, is a potent microtubule depolymerizing agent.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.